Skip to Content

EAN 2025: Efgartigimod Approved in EU for CIDP

At EAN 2025, Professor Giuseppe Lauria presented results from the ADHERE trial, showing that efgartigimod is effective in treating CIDP with a response rate of around 60%. Recently, efgartigimod was approved in the EU for the treatment of CIDP. Efgartigimod is administered subcutaneously, which reduces the need for hospital-based treatment and minimizes side effects.

Giuseppe Lauria

Få tilgang

Hvis du er lege, sykepleier eller annen helsepersonell, kan du få tilgang til hele artikkelen ved å opprette en profil på BestPractice Nordic.

Back to top